IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v6y2005i3p223-232.html
   My bibliography  Save this article

A cross-national perspective on cost of illness

Author

Listed:
  • Johan Polder
  • Willem Meerding
  • Luc Bonneux
  • Paul Maas

Abstract

No abstract is available for this item.

Suggested Citation

  • Johan Polder & Willem Meerding & Luc Bonneux & Paul Maas, 2005. "A cross-national perspective on cost of illness," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 223-232, September.
    • Handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:223-232
    DOI: 10.1007/s10198-005-0295-0
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-005-0295-0
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-005-0295-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Ament, Andre & Evers, Silvia, 1993. "Cost of illness studies in health care: a comparison of two cases," Health Policy, Elsevier, vol. 26(1), pages 29-42, November.
    2. Drummond, Michael & Jonsson, Bengt & Rutten, Frans, 1997. "The role of economic evaluation in the pricing and reimbursement of medicines," Health Policy, Elsevier, vol. 40(3), pages 199-215, June.
    3. Henke, Klaus-Dirk & Behrens, Cornelia S., 1986. "The economic cost of illness in the Federal Republic of Germany in the year 1980," Health Policy, Elsevier, vol. 6(2), pages 119-143.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gudrun Biffl & Thomas Leoni & Christine Mayrhuber, 2009. "Arbeitsplatzbelastungen, arbeitsbedingte Krankheiten und Invalidität," WIFO Studies, WIFO, number 35901.
    2. Gudrun Biffl & Anna Faustmann & Doris Gabriel & Thomas Leoni & Christine Mayrhuber & Eva Rückert, 2012. "Psychische Belastungen der Arbeit und ihre Folgen," WIFO Studies, WIFO, number 44034.
    3. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    4. Agata Łaszewska & Johannes Wancata & Rebecca Jahn & Judit Simon, 2020. "The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1075-1089, September.
    5. Heijink, Richard & Noethen, Manuela & Renaud, Thomas & Koopmanschap, Marc & Polder, Johan, 2008. "Cost of illness: An international comparison: Australia, Canada, France, Germany and The Netherlands," Health Policy, Elsevier, vol. 88(1), pages 49-61, October.
    6. Christina Wenig, 2012. "The impact of BMI on direct costs in Children and Adolescents: empirical findings for the German Healthcare System based on the KiGGS-study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 39-50, February.
    7. László Gulácsi, 2007. "The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 83-88, June.
    8. Giuseppe Turchetti & S. Bellelli & M. Amato & S. Bianchi & P. Conti & A. Cupisti & V. Panichi & A. Rosati & F. Pizzarelli, 2017. "The social cost of chronic kidney disease in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 847-858, September.
    9. Gudrun Biffl & Thomas Leoni, 2008. "Arbeitsbedingte Erkrankungen. Schätzung der gesamtwirtschaftlichen Kosten mit dem Schwerpunkt auf physischen Belastungen," WIFO Studies, WIFO, number 35099.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Huajie Jin & Paul McCrone, 2015. "Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies," PharmacoEconomics, Springer, vol. 33(4), pages 341-353, April.
    2. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    3. Henschke, Cornelia & Sundmacher, Leonie & Busse, Reinhard, 2013. "Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation," Health Policy, Elsevier, vol. 109(3), pages 263-269.
    4. Michael Drummond & Adrian Towse, 2019. "Is rate of return pricing a useful approach when value-based pricing is not appropriate?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 945-948, September.
    5. David B. Evans & Dan Chisholm & Tessa Tan-Torres Edejer, 2012. "Generalized Cost-effectiveness Analysis: Principles and Practice," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 48, Edward Elgar Publishing.
    6. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    7. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    8. Buzby, Jean C. & Roberts, Tanya & Allos, Ban Mishu, 1997. "Estimated Annual Costs of Campylobacter-Associated Guillain-Barre Syndrome," Agricultural Economic Reports 33969, United States Department of Agriculture, Economic Research Service.
    9. Syed Mohiuddin, 2014. "A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 359-372, August.
    10. Lundkvist, Jonas & Jonsson, Bengt & Rehnberg, Clas, 2006. "The costs and benefits of regulations for reimbursement of new drugs," Health Policy, Elsevier, vol. 79(2-3), pages 337-344, December.
    11. Anthony Harris & Jing Jing Li & Karen Yong, 2016. "What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study," PharmacoEconomics, Springer, vol. 34(4), pages 393-402, April.
    12. Lu, Tsung-Hsueh & Jen, Ian & Chou, Yiing-Jenq & Chang, Hong-Jen, 2005. "Evaluating the comparability of different grouping schemes for mortality and morbidity," Health Policy, Elsevier, vol. 71(2), pages 151-159, February.
    13. Rieka von der Warth & Philip Hehn & Jan Wolff & Klaus Kaier, 2020. "Hospital costs associated with post-traumatic stress disorder in somatic patients: a retrospective study," Health Economics Review, Springer, vol. 10(1), pages 1-8, December.
    14. Susie El Saadany & Douglas Coyle & Antonio Giulivi & Mohammad Afzal, 2005. "Economic burden of hepatitis C in Canada and the potential impact of prevention," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 159-165, June.
    15. Lili Wang & Lei Si & Fiona Cocker & Andrew J. Palmer & Kristy Sanderson, 2018. "A Systematic Review of Cost-of-Illness Studies of Multimorbidity," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 15-29, February.
    16. Shiell, Alan & Law, Matthew G, 2001. "The cost of hepatitis C and the cost-effectiveness of its prevention," Health Policy, Elsevier, vol. 58(2), pages 121-131, November.
    17. Hugh S.E. Gravelle, 1998. "Ex post Value Reimbursement for Pharmaceuticals," Medical Decision Making, , vol. 18(2_suppl), pages 27-38, April.
    18. Carine Franc & Laurent Granier & Sébastien Trinquard, 2013. "Tarif forfaitaire de responsabilité : quels impacts sur le pharmacien ?," Working Papers halshs-00800457, HAL.
    19. Chiara Bonassi & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica," Working Papers CERM 02-2007, Competitività, Regole, Mercati (CERM).
    20. Keith Tolley;Gareth Morgan;Ray Cartwright;Rhys Williams, 1998. "Economic Aspects of Non-Hodgkin's Lymphoma," Series on Health 000436, Office of Health Economics.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:223-232. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.